VapoCoolShot, Inc., a leading innovator in pain management technology, has partnered with MedPro, the nation’s top contract medical sales organization, to bring CoolJect® to acute and non-acute markets across the U.S. CoolJect, a cutting-edge FDA-cleared device and spray, offers precision comfort with fast, effective, lower-cost topical anesthetic for injections and minor surgical procedures.
Bill Sparks, MedPro CEO, commented: “CoolJect’s revolutionary technology is a vastly superior solution for topical anesthetics; current solutions are time consuming and costly which drains the healthcare system of billions every year. We’ve already had some great wins based on the practicality of converting to CoolJect and we are seeing marked acceleration as more patients and caregivers experience the product.”
The device promises to anesthetize quickly and accurately with its Targeted Mist™ technology, providing gentle, consistent, and targeted coverage that drastically reduces waste and lowers costs to healthcare providers. CoolJect combines a high-efficiency nozzle with a non-toxic, non-flammable gas canister and is used to provide a targeted cooling effect on the skin which lessens pain associated with injections. It is also used for minor surgical procedures such as lancing boils, incisions, drainage of small abscesses and sutures, and the temporary relief of minor sports injuries like sprains, bruising, cuts, and abrasions. CoolJect is intended for topical application to skin, intact mucous membrane (oral cavity, nasal passageways, lips), and minor open wounds.
This year alone, nearly 100 million Americans will experience fear of injection pain, according to a recent industry study1. As a result, these patients will delay or entirely avoid recommended procedures (i.e., cannulations, insulin injections, bloodwork, vaccinations, etc.), giving rise to comorbidities and introducing tremendous long-term costs to the healthcare system2. VapoCoolShot is the first company to address all these issues in a more efficient package with its flagship product CoolJect.
Ethan Mandelup, VapoCoolShot CEO, commented: “We are incredibly proud to see the swift expansion and embrace of CoolJect due to overwhelmingly positive feedback from patients and physicians alike.
VapoCoolShot is a company dedicated to empowering healthcare providers to deliver more comfort to their patients and it’s thrilling to fulfill this commitment by providing a low cost, highly effective tool to use across a myriad of use cases. What’s more, we know that we’ve found the ideal partner in MedPro and their national sales model to help us bring CoolJect® to caregivers and patients across all healthcare markets.”
The results and savings are clear; users are sure to provide improved care while enjoying space, cost and shipping savings by switching to CoolJect®. Its canisters are roughly half the size of comparable vapocoolant products, use up to 50% less gas than the competition per second while offering the same number of effective uses, and require no Hazmat shipping fees.
Contact your local MedPro rep to learn more about CoolJect®.
1 Love AS, Love RJ. Considering Needle Phobia among Adult Patients During Mass COVID-19 Vaccinations. J Prim Care CommunityHealth. 2021;12:21501327211007393. doi:10.1177/21501327211007393
2 Duncanson E, Le Leu RK, Shanahan L, et al. The prevalence and evidence-based management of needle fear in adults with chronic disease: A scoping review. PLoS One. 2021;16(6):e0253048. Published 2021 Jun 10. doi:10.1371/journal.pone.0253048